Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets
开发单剂量自扩增 RNA 疫苗,用于增强已有的流感病毒免疫力,驱动 B 和 T 细胞对保守靶点的反应
基本信息
- 批准号:10484741
- 负责人:
- 金额:$ 10.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-10 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntibodiesAntibody ResponseAntibody SpecificityAntibody titer measurementAntigensAutomobile DrivingB-LymphocytesBirdsCOVID-19COVID-19 pandemicCessation of lifeClinicClinicalCoupledCustomDataDevelopmentDiseaseDoseEpidemiologyEpitopesEventExposure toFerretsFormulationFutureHemagglutininHumanImmuneImmune responseImmunityInactivated VaccinesIndividualInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A virusInfluenza B VirusInfluenza vaccinationInvestigational DrugsLeadLearningLifeLipidsMaintenanceModelingMorbidity - disease rateMusMutationNonstructural ProteinNucleic Acid VaccinesNucleoproteinsPharmaceutical PreparationsPhasePopulationPopulation HeterogeneityProblem SolvingProcessRNARNA amplificationRNA vaccineReaction TimeRecording of previous eventsRoleSafetySecondary ImmunizationSmall Business Innovation Research GrantSpecificitySpeedT cell responseTechnologyTimeUpdateVaccinationVaccineeVaccinesVariantVirusantigen-specific T cellsbasebooster vaccinedesignflexibilityimmunogenicityimprovedinfluenza infectioninfluenza virus straininfluenza virus vaccineinfluenzavirusinterestmanufacturing processmortalitynanoparticleneutralizing antibodynonhuman primatepandemic diseasepandemic influenzapandemic preparednesspersonalized approachpersonalized medicineprotective efficacypublic trustrespiratory infection virusrespiratory pathogenrespiratory virusresponsestemuniversal influenza vaccinevaccination outcomevaccine acceptancevaccine developmentvaccine distributionvaccine efficacyvaccine platformzoonotic spillover
项目摘要
Project Summary
While a universal influenza vaccine, providing life-long protective immunity against all current and future
drifted and shifted subtypes of influenza virus after 2 or 3 doses, would be a game-changing solution to
reducing the global burden of influenza and its associated morbidity and mortality, other approaches to
solving this problem are urgently needed. There is still much to learn about immune responses to respiratory
pathogens, such as influenza virus, and vaccine approaches that drive life-long immunity to respiratory viruses
have yet to be demonstrated in humans. Therefore, we propose to develop a broadly protective influenza
booster vaccine that can be administered, either seasonally or during pandemics, to individuals with prior
exposures to either natural infection or seasonal vaccination. Given the non-uniform influenza immune history
in a given population of individuals, it is likely that booster vaccines will need to be customized either at the
individual or regional level, based on local influenza virus epidemiology or vaccine uptake. Nucleic acid vaccine
platforms provide the ideal framework for such personalized-medicine approaches, due to the flexibility of
development, as typified by the ongoing COVID-19 pandemic. As proof-of-concept, here we propose to apply
our clinical-stage replicating RNA vaccine platform to develop a booster vaccine targeting the conserved
hemagglutinin stem and nucleoprotein of group 1 influenza viruses and evaluating immunogenicity and
efficacy against heterologous group 1 influenza virus infections in mouse and ferret models of pre-existing
influenza virus immunity. These data will inform the feasibility of such an approach and characterize what
types of pre-existing immunity, in terms of anti-hemagglutinin antibody specificity and magnitude, are
required for booster vaccine efficacy. As these pre-existing antibody criteria are easily assessed in humans, it is
likely that a personalized approach to influenza booster vaccination is achievable.
项目摘要
虽然是一种通用流感疫苗,提供终身保护性免疫力,
在2或3次剂量后,流感病毒的亚型发生漂移和转移,这将是一个改变游戏规则的解决方案,
减少流感及其相关发病率和死亡率的全球负担,
解决这个问题是迫切需要的。关于呼吸道感染的免疫反应,
病原体,如流感病毒,和疫苗的方法,驱动终身免疫呼吸道病毒
尚未在人类身上得到证实。因此,我们建议研制一种广泛保护性的流感疫苗,
加强疫苗,可以在季节性或大流行期间给予先前患有
自然感染或季节性疫苗接种。鉴于流感免疫史的不一致性
在特定的人群中,很可能需要在
根据当地流感病毒流行病学或疫苗接种情况,在个人或区域一级进行评估。核酸疫苗
平台为这种个性化医疗方法提供了理想的框架,因为它具有灵活性,
发展,以持续的COVID-19疫情为代表。作为概念验证,我们建议在此应用
我们的临床阶段复制RNA疫苗平台,以开发针对保守的
组1流感病毒的血凝素干细胞和核蛋白并评价免疫原性,
在预先存在的小鼠和雪貂模型中抗异源1型流感病毒感染的效力
流感病毒免疫。这些数据将为这种方法的可行性提供信息,并描述
就抗血凝素抗体的特异性和强度而言,预先存在的免疫力的类型如下:
增强疫苗效力所需的。由于这些预先存在的抗体标准很容易在人体中进行评估,
个性化的流感加强疫苗接种方法可能是可以实现的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jesse Hong-Sae Erasmus其他文献
Jesse Hong-Sae Erasmus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jesse Hong-Sae Erasmus', 18)}}的其他基金
Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets
开发单剂量自扩增 RNA 疫苗,用于增强已有的流感病毒免疫力,驱动 B 和 T 细胞对保守靶点的反应
- 批准号:
10620283 - 财政年份:2022
- 资助金额:
$ 10.47万 - 项目类别:
Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis
开发针对肠道病毒 D68 感染的适应性 RNA 疫苗,用于预防急性弛缓性脊髓炎
- 批准号:
10325201 - 财政年份:2021
- 资助金额:
$ 10.47万 - 项目类别:
Development of a novel replicating viral RNA vaccine platform
新型复制病毒RNA疫苗平台的开发
- 批准号:
10161283 - 财政年份:2018
- 资助金额:
$ 10.47万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 10.47万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 10.47万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 10.47万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 10.47万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 10.47万 - 项目类别: